- Home
- TZUP vs ZBIO Comparison
TZUP vs ZBIO Comparison
Compare TZUP & ZBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TZUP
- ZBIO
- Stock Information
- Founded
- TZUP 2020
- ZBIO 2019
- Country
- TZUP United States
- ZBIO United States
- Employees
- TZUP N/A
- ZBIO N/A
- Industry
- TZUP
- ZBIO
- Sector
- TZUP
- ZBIO
- Exchange
- TZUP NYSE
- ZBIO NYSE
- Market Cap
- TZUP 66.7M
- ZBIO 389.2M
- IPO Year
- TZUP N/A
- ZBIO 2024
- Fundamental
- Price
- TZUP $9.95
- ZBIO $11.18
- Analyst Decision
- TZUP
- ZBIO Strong Buy
- Analyst Count
- TZUP 0
- ZBIO 7
- Target Price
- TZUP N/A
- ZBIO $32.29
- AVG Volume (30 Days)
- TZUP 316.9K
- ZBIO 180.5K
- Earning Date
- TZUP 08-11-2025
- ZBIO 08-16-2025
- Dividend Yield
- TZUP N/A
- ZBIO N/A
- EPS Growth
- TZUP N/A
- ZBIO N/A
- EPS
- TZUP N/A
- ZBIO N/A
- Revenue
- TZUP $487.00
- ZBIO $15,000,000.00
- Revenue This Year
- TZUP N/A
- ZBIO $165.20
- Revenue Next Year
- TZUP N/A
- ZBIO $63.75
- P/E Ratio
- TZUP N/A
- ZBIO N/A
- Revenue Growth
- TZUP N/A
- ZBIO N/A
- 52 Week Low
- TZUP $2.02
- ZBIO $5.83
- 52 Week High
- TZUP $13.44
- ZBIO $26.25
- Technical
- Relative Strength Index (RSI)
- TZUP N/A
- ZBIO N/A
- Support Level
- TZUP N/A
- ZBIO N/A
- Resistance Level
- TZUP N/A
- ZBIO N/A
- Average True Range (ATR)
- TZUP 0.00
- ZBIO 0.00
- MACD
- TZUP 0.00
- ZBIO 0.00
- Stochastic Oscillator
- TZUP 0.00
- ZBIO 0.00
About TZUP THUMZUP MEDIA CORP
Thumzup Media Corp operates in the social media branding and marketing industry. The company operates in a single business segment which is social media marketing. The Thumzup App works on both iPhone and Android mobile operating systems and connects brands and people who use and love these brands. The easy-to-use dashboard allows advertisers to programmatically customize their campaigns. Cash payments are made to App users/creators through Venmo and PayPal.
About ZBIO ZENAS BIOPHARMA INC
Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them.